ROTHBLATT MARTINE A sold $5.0M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $525.36 ($512.50–$532.39, $4.99M total) across 18 trades on 2026-08-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, trade date (Aug 6), and price range, under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this specific filing is typically low-signal due to 10b5-1 pre-arrangement.
What to watch
Indirect holdings and multiple small trades across a price band can reflect diversification or liquidity needs rather than a view on near-term fundamentals.
Background
The article is an SEC Form 4 insider transaction filing for United Therapeutics, reported by CEO Chairperson Martine Rothblatt as an indirect holding sale.
Ticker impact
United Therapeutics Form 4 shows CEO Chairperson Martine Rothblatt sold about 9,500 shares via a 10b5-1 plan at $512.50 to $532.39.
Likely limited near-term impact; any reaction should fade unless accompanied by other company-specific news.
The filing specifies an open-market sale under a pre-arranged Rule 10b5-1 plan, which typically reduces the signal strength versus discretionary sales.
Market effects
No clear sector read-through from a single 10b5-1 insider sale at a large biotech/pharma name.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, the market may overreact; the disclosure could be largely mechanical rather than a bearish signal.
Key entities
- issuerUNITED THERAPEUTICS Corp
US-listed company whose insider transaction is disclosed on Form 4.
- insiderROTHBLATT MARTINE A
Chairperson and CEO reporting an open-market sale of shares via a 10b5-1 plan.
